ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~3#܈ ~~<#܈ ~~4#܈ ~~7#܈ ~~83ffff̙̙3f3fff3f3f33333f33ARGOS THERAPEUTICS INC dPART I3Our Development Programs&MPhase 2 Combination Therapy Cli&\Description and Development StahPART IIw PART II (1)&RConsolidated Statements of Oper&Consolidated Balance Sheet Data&fResults of Operations YearOverY&Research and Development Expens Cash Flows&Liability for Warrants and the +ShareBased Compensation&;Contractual Obligations and ComZSPART III!}eSummary Compensation Table&lOutstanding Equity Awards as of&L2017 Compensation of NonEmploye&Equity Compensation Plan Inform&SSecurity Ownership of Certain BDirector IndependencePART IV PART IV (1)]B PART IV (2)os PART IV (3) SIGNATURES&YINDEX TO CONSOLIDATED FINANCIAL"CONSOLIDATED BALANCE SHEETS&CONSOLIDATED STATEMENTS OF (1)&ZCONSOLIDATED STATEMENTS OF COMP&,CONSOLIDATED STATEMENTS OF CHAN&ACONSOLIDATED STATEMENTS OF CASH&2 Fair Value of Financial Instr&2 Fair Value of Financial I (1)&2 Fair Value of Financial I (2)&g2 Fair Value of Financial I (3)&m2 Fair Value of Financial I (4)&Impairment of Centerpoint Facil4 Property and Equipment&Centerpoint Facility and Constr5 Income Taxes'5 Income Taxes (1)H5 Income Taxes (2)&X6 Notes Payable and Convertiblep 10 Warrants10 Warrants (1)10 Warrants (2)&.2014 Stock Incentive Plan and 2&9Valuation Assumptions for Stock&4Valuation Assumptions for S (1)&`Other Information for Stock Opt&Other Information for Stock (1)13 Commitments 15 Net Loss Per Share #15 Net Loss Per Share (1)&J(16 Selected Quarterly Data unau&@16 Selected Quarterly Data (1)&[Deferred Tax Asset Valuation AllLicense Agreementz PATENT RIGHTSLummy Hong Kong Co Ltd!gLummy Hong Kong Co Ltd (1)&CERTIFICATIONS PURSUANT TO 18 U&ۯCERTIFICATIONS PURSUANT TO (1) l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@PART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 0}       ARGOS THERAPEUTICS INC 10-K 04/02/2018 ARGOS THERAPEUTICS, INC.Delaware 56-2110007' (State or other jurisdiction of (I.R.S. Employer& incorporation or organization) Identification No.)   4233 Technology Drive~  Durham, North Carolina0((Address of principal executive offices) (Zip Code)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,B||pd:cA=PF0*8X> @ l  4.63  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } :}  4     ARGOS THERAPEUTICS INC 10-K 04/02/2018PART IItem 1. Business~  Item 1A. Risk Factors~ * "Item 1B. Unresolved Staff Comments~ z Item 2. Properties~ z! Item 3. Legal Proceedings~ z' Item 4. Mine Safety Disclosures~ zPART II.&Item 5. Market for Registrant?s Common~ ~/'Equity, Related Stockholder Matters and-%Issuer Purchases of Equity Securities'Item 6. Selected Financial Data~ 4,Item 7. Management?s Discussion and Analysis~ 80of Financial Condition and Results of Operations-%Item 7A. Quantitative and Qualitative~  %Disclosures About Market Risk6.Item 8. Financial Statements and Supplementary~  Data.1)Item 9. Changes in and Disagreements with~ /'Accountants on Accounting and Financial Disclosure.( Item 9A. Controls and Procedures~ "Item 9B. Other Information~ PART III.&Item 10. Directors, Executive Officers~ DlvLI*Mc }C !"#$%&'()*+,-./0123 and Corporate Governance'!Item 11. Executive Compensation~ !"."&Item 12. Security Ownership of Certain~ "R4#,Beneficial Owners and Management and Related$Stockholder Matters2%*Item 13. Certain Relationships and Related~ %^/&'Transactions, and Director Independence.'&Item 14. Principal Accountant Fees and~ 'n(Services)PART IV)1*)Item 15. Exhibits and Financial Statement~ *r+ Schedules",Item 16. Form 10-K Summary~ ,- Signatures~ -. Schedule II .F-43/0$1____________________________12)Created by Morningstar Document Research.03(http://documentresearch.morningstar.com/,|c+ UA"rK?3 =PF0*8X> @332211 l  (IL  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART I!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 0} $ } a} $ } $} > (     ARGOS THERAPEUTICS INC 10-K 04/02/2018 Our Development ProgramsProduct CandidatePrimary IndicationStatus Rocapuldencel-T  mRCC  ?1 )Ongoing ADAPT trial; enrollment completed     < 4in July 2015; IDMC recommended study discontinuation     . &for futility in February 2017; ongoing     / 'discussions with FDA regarding protocol     0 (amendment and statistical analysis plan;3+interim analysis planned for second quarterof 2018 ?5-Planned Phase 2 clinical trial in combination,$with a checkpoint inhibitor expected4,to open for enrollment as early as the first/'half of 2019 subject to supportive data1)from the ADAPT trial and discussions with3+the FDA and our obtaining financing to fund the trial.AGS-004 HIV ?6.Ongoing second stage of investigator-initiated5-clinical trial in combination with vorinostatfor HIV eradication ?,$Planned investigator-initiated Phase4,2 clinical trial for long-term viral control3+in pediatric patients provided that resultsD l|pdz!>1Qqdn^ !"#$%&'     0 (from ongoing trial in adult HIV patients!!!!!0!(are favorable and government funding and"""""(" necessary approvals are obtained#$$%____________________________1&)Created by Morningstar Document Research.0'(http://documentresearch.morningstar.com/ x=PF0*8X> @"''&&%% l   [  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } I } $ } } $      ARGOS THERAPEUTICS INC 10-K 04/02/20182*Phase 2 Combination Therapy Clinical TrialOutcome(N=21)  Median OS (1)  30.2 months Median PFS (2)  11.2 months Complete response (3)  0 patients Partial response (4)  9 patients Stable disease (5)  4 patientsImmune response1)CD8+ CD28+ memory T-cells correlated with4,OS, PFS and reduced metastatic tumor burden;5-IL-2 and interferon- g (IFN- g ) recovery$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0?vj^R}Gs" =PF0*8X> @           l  Kh  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } $ } $} 1      ARGOS THERAPEUTICS INC 10-K 04/02/2018*"Description and Development Status ?-%a phase 2b clinical trial of AGS-004;  ?1 )a phase 2a clinical trial of AGS-004; and  ?, $a phase 1 clinical trial of AGS-004.  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$p,~rfZyma9=PF0*8X> @  l  2v  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } %} $                    ARGOS THERAPEUTICS INC 10-K 04/02/2018PART II' Year ended December 31, 2016 High Low  First quarter ~    LB@  Second quarter  fffffvq@  ~ ~   Third quarter  a@  ~ .  Fourth quarter ~   ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(Tu@qeY1=PF0*8X> @j          l  }  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } %} $                    ARGOS THERAPEUTICS INC 10-K 04/02/2018PART II' Year ended December 31, 2017 High Low  First quarter   ףp=j\@   @  Second quarter  ffffff0@   p= ף@   Third quarter  "@   (\ @  Fourth quarter  333333@   (\@  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(Tu8]QE=PF0*8X> @j          l  )ԧڬ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 8} $ } } $ } }  $ } } $ } } $ } } $ )     ARGOS THERAPEUTICS INC 10-K 04/02/20183+Consolidated Statements of Operations Data:Year Ended December 31,  ~ v ~ z ~ ~ ~  ~  Revenue ~    ~ |x  ~   ~ 9  ~ s  Operating expenses:                     Research and development  ~ M   ~     ~    ~ "    ~ ) " General and administrative  ~    ~     ~    ~ b   ~  0(Impairment of property and equipment (1) ? ?    ?  ~ ;-~ yRestructuring costs (2) ? ?    ?   ?~ &p1)Gain on disposal of impaired property (3) ? ?    ?   ?~ 2WOperating loss~ v9~   ~  >   ~ {~ Other income (expense):     Interest income~ Bp~ R  ~    ~ ~ Interest expense~ ~~ l  ~  Fu  ~ ~ ^'0(Gain on early extinguishment of debt (4) ? ?    ?   ?~ ӏ1)Change in fair value of warrant liability~ b ?    ?  ~ {=~ f~ Investment tax credits ?~ 2    ?   ? ?Other (expense) income~ ~   ~  F  ~ F~ #Other income (expense), net~ "~ :  ~  "8w  ~ ~ ^7Net loss~ K~ vJ  ~  ^E+  ~ k[~ jXS5-Accretion of redeemable convertible preferred~ Q#~ P    ?   ? ? stock7/Less: Preferred stock dividend due to exchanges~ 0} ?    ?   ? ?of preferred sharesD0lui]Qj?&RD, !"#$%&'(4 ,Net loss attributable to common stockholders ~ rt  ~   ~ ^E+  ~ k[  ~ jXS /!'Basic and diluted net loss attributable!!p= !!!q= ף0O!! ! HzGR! ! !R@!!!fffff*!(" to common stockholders per share1#)Basic and diluted weighted average shares##~ ####~ #~5## # ~ # :n># # #~ #za###~ #+#$ outstanding%$&____________________________1')Created by Morningstar Document Research.0((http://documentresearch.morningstar.com/ _=PF0*8X> @((''&&!!!!!! !!!!             l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 0.} $ } } $ } }  $ } } $ } } $ } } $      ARGOS THERAPEUTICS INC 10-K 04/02/2018( Consolidated Balance Sheet Data:As of December 31,  ~ v ~ z ~ ~ ~  ~ - %Cash, cash equivalents and short-term ~ Z2   ~ h   ~ e  ~ =   ~     investments  Total assets  ~ ~0    ~ zX   ~ df   ~ ,   ~ , # Total long-term liabilities  ~ =g   ~    ~ s-    ~ j h   ~ ^t .&Redeemable convertible preferred stock~ V ?    ?   ? ?,$Total stockholders? (deficit) equity~ ~ y  ~  F  ~ ~x~ e$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.@ th\&_7 =PF0*8X> @r         l  $-b  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 1} $ }  } $ }  }  $ }  } $ }  } $} $ }  } $ }  } $ }  } $ }  } $ $!!!!!!!!!! ! ! ! ! !!!!!!!!!!!!!!!!!!!ARGOS THERAPEUTICS INC 10-K 04/02/201880Results of Operations Year-Over-Year Comparisons Year Ended ~    % Year Ended~  %    December 31,           December 31,  ~  ~   Change  Change ~ ~ ~   Change  Change   (in thousands) Revenue ~   ~   ~     9Y@ % ~   ~   ~     T@ % Operating expenses:                                 Research and development~ V~ bR  ~    E %~ ~ V~ fffff&C  %"General and administrative~ ~ ^  ~  r  ffffff, %~ ~ ~ 1~ v  %,$Impairment of property and equipment~  ~ ک  ~  F   * ?~  ~   * Restructuring costs ?~ B^  ~  B^   * ? ? ? * -%Gain on disposal of impaired property ?~   ~     * ? ? ? *        Total operating expenses~ @~   ~    fffff4@ %~ u~ @~ f;  %      Loss from operations~ ~ 0  ~  ^a  ffffff3 %~ r~ ~ J<fffff;  %      Interest income~ ~   ~  "  )@ %~ f~ ~ ~   %Interest expense~ F~   ~  N  L:@ %~ ~ F~ 5  %,$Gain on early extinguishment of debt ?~ $  ~  $   * ? ? ? * 1)Change in fair value of warrant liability~ ~ ZD  ~  4   * ?~ ~  * Other (loss) income~ ~ *  ~  V   *~ ~ ~  *       Net loss~ r~  ~    7@ %~ no~ r~ T=  %D%lpdXL_F%O X&y !!!"!#! $!____________________________1")Created by Morningstar Document Research.0#(http://documentresearch.morningstar.com/ <=PF0*8X> @ ## "" !!                   l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 1} $ } U} $ } U}  $ } U} $                            ARGOS THERAPEUTICS INC 10-K 04/02/2018)!Research and Development ExpensesYear Ended December 31,  ~ ~ ~  ~    (in thousands)/ 'Direct research and development expense              by program: Rocapuldencel-T ~ _  ~ ^  ~ *t AGS-004~ ~ *  ~    Other~ ~ 2    ? -%Total direct research and development~ d~   ~  u program expense,$Commercial manufacturing development~ ~ "5  ~  . 1)Indirect research and development expense~ L~ p  ~  N .&Total research and development expense~ ~ V ~  bR $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 sg[ -6k=PF0*8X> @r          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 0} $ }  } $ }  }  $ } U} $                        ARGOS THERAPEUTICS INC 10-K 04/02/2018 Cash FlowsYear Ended December 31,  ~ ~ ~  ~    (in thousands)' Net cash (used in) provided by:             Operating activities ~ F  ~ n  ~ ~  Investing activities  ~ n   ~ &    ~  Financing activities~ I~ 6  ~   /'Effect of exchange rate changes on cash~ ~   ~  " 0(Net increase (decrease) in cash and cash~ ~ j ~    equivalents$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0~r7^)l`8=PF0*8X> @r          l  *  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash FlowsShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } U5} $ } $} $} $ } U} $                             ARGOS THERAPEUTICS INC 10-K 04/02/2018D<Liability for Warrants and the Related Changes in Fair ValueDecember 31, 2016December 31, 2017     " Exercise price of warrants ~   ~  & Closing underlying stock price ~   ~  ' Expected stock price volatility  ~ R %  ~  % Expected life (in years)   RQ@    p= ף @ Risk-free interest ratezG? %RQ@ %Expected dividend yield~  %~  %-%Valuation per common share underlyingq= ףN@\(\? each warrant3+Total liability for warrants on the balance~ 9~ R;  sheet4,Decrease in fair value during the year ended~ {=~ f$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:c dXL@4- cRbVJ"=PF0*8X> @z     l   ;  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the !Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } %} $ }  } $} $ }  } $} $ } } $                    ARGOS THERAPEUTICS INC 10-K 04/02/2018 Share-Based Compensation~ ~~  ~   Risk-free interest rate   ffffff@ %   ? %   Gz@ % Dividend yield  ~  %  ~  %  ~  %' Expected option term (in years)  ~    ~    ~    Volatility  ~ ^ %  ~ J %  ~ Z % $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T|pd B=PF0*8X> @2    l  3R  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } $4} $ }  } $ }  }  $ } } $ }  } $ } $} $      ARGOS THERAPEUTICS INC 10-K 04/02/2018/'Contractual Obligations and CommitmentsPayments Due by Period   Total   Less Than   1-3 Years   3-5 Years   More Than       1 Year          5 Years0 (Operating leases for existing facilities ~ ..  ~ j   ~ F  ~   ~ v   and equipment2 *Convertible note payable to Pharmstandard,  ~     ?    ?   ~     ? including interest-%Convertible note payable to Invetech,~ Z[~ R  ~   G   ? ?including interest1)Convertible note payable to Saint-Gobain,~ ~$~ j  ~     ? ?including interest3+Note payable to Medinet, including interest~ N~ N    ?   ? ?/'Other notes payable, including interest~ :~ :    ?   ? ? Total~ ڏ~ Z| ~  bo  ~ ~ v$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:? ymaUn]?UznF=PF0*8X> @            l  d  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and ComSummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } %} $ } } $ } $4      ARGOS THERAPEUTICS INC 10-K 04/02/2018PART III Name  Age  Position Jeffrey D. Abbey ~  . &President, Chief Executive Officer and     Director# Charles A. Nicolette, Ph.D. ~  3 +Chief Scientific Officer and Vice President    # of Research and DevelopmentRichard D. Katz, M.D.~ 2*Vice President and Chief Financial OfficerLori R. Harrelson~ !Vice President of Finance"Hubert Birner, Ph.D.(1)(3)~ *"Chairman of the Board of DirectorsRobert F. Carey(1)(2)~ Director Igor Krol~ Director!Richard G. Morrison(1)(2)~ JDirector!Irackly Mtibelishvily (3)~ Director'Sander van Deventer M.D., Ph.D.~ Director$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:t8y5ZuQ."=PF0*8X> @ l  u~  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART III!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 2} $ }  } $ }  }  $ }  } $ } y} $ }  } $ }  } $ } y} $      ARGOS THERAPEUTICS INC 10-K 04/02/2018"Summary Compensation Table#Name and Principal Position YearSalary   Bonus OptionStock Awards ($) (4) All Other Total ($)      ~    ($) (1)(2)  Awards       Compensation               ($) (3)      ($) (5) Jeffrey D. Abbey (6)  ~    ~ L   ~ L   ~ FhW    ___   ~ ^   ~ | - %President and Chief Executive Officer  ~    ~ Bw   ~ F\   ~ >   ~    ~    ~ v " Charles A Nicolette, Ph.D.  ~    ~    ~ V   ~ ~)    ____   ~ N   ~  H 2*Vice President of Research and Development~ ~ "  ~  ?  ~ r,~ A~ #~ {O$and Chief Scientific OfficerRichard D. Katz (7)~ ~   ~    ~ z ___~ .~ B/2*Vice President and Chief Financial Officer     $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2eznbXndV<=PF0*8X> @       l  0ǜc  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } !} $ } U} $ } U} $ } } U} $ }  0     ARGOS THERAPEUTICS INC 10-K 04/02/201891Outstanding Equity Awards as of December 31, 2017 NameNumber of SecuritiesNumber of Securities  Option Option    Underlying   Underlying  Exercise   Expiration    Unexercised   Unexercised   Price ($)  Date    Options (#)   Options (#)    Exercisable   Unexercisable Jeffrey D. Abbey  ~      ?   ~ R~   7/2/18~ v ?  ~  R~   12/5/18~ f' ?  ~  R~   12/10/20~ 1 ?  ~  R~   4/10/22~ # ?  ~  R~   12/11/22~ - ?   ]@  11/1/23~ 2 ?   ]@  11/11/23~ &~ ~    33333s^@  7/27/24~ :"   33333s^@  7/27/24~ :" ?   33333s^@  7/27/24~ :~ *#~   ~  r  6/16/25~ >I~ z~    fffffb@  6/12/26 ?~ -~   ~    1/18/27          #Charles A. Nicolette, Ph.D.~ r  ?  ~  R~   7/2/18~  ?  ~  R~   12/5/18~ j  ?  ~  R~   12/10/20~  ?  ~  R~   4/10/22D)locWK4MA|.k.z !"#$%&'()*+,-./   ~     ?   ~ R~   12/11/22!!!~ !J~!!! !?!! ! ! ]@! ! !11/1/23"""~ "B""" "?"" " " ]@" " "11/11/23###~ # ###~ #~ ## # # 33333s^@# # #7/27/24$$$~ $$$$$$$ $ $ 33333s^@$ $ $7/27/24%%%~ %$%%%~ %~ %% % ~ % r% % %6/16/25&&&~ &F3&&&~ &vU~ && & & fffffb@& & &6/12/26'''~ ''''~ '~ '' ' ~ ' ' ' '1/18/27(((((((((( ( ( ( ( ()Richard D. Katz))~ )W)))~ )~~ )) ) ~ ) ) ) )7/10/26*** *?***~ * R~ ** * ~ * * * *1/18/27+,$-____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$T ,=y*g)W}U=PF0*8X> @//..--          l  ߺ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } '} $ } U} $ } U}  $ } U} $                         ARGOS THERAPEUTICS INC 10-K 04/02/20183+2017 Compensation of Non-Employee Directors NameFees Earned or Option Awards   Total    Paid in Cash ~    ~    ~    ~   Hubert Birner, Ph.D.  ~     ~ j&   ~ z/  Robert F. Carey  ~ 2W   ~ j&   ~ }   Igor Krol  ~ q   ~ j&   ~ j Irackly Mtibelishvily~ " ?  ~  " Richard G. Morrison (2)~ ~ :  ~  6 !Ralph Snyderman, M.D. (3)~  ?  ~   ( Sander van Deventer, M.D., Ph.D.~ b[~ j&  ~  ʁ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2 ui]Q7%l=PF0*8X> @B     l  B  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 0.} $ }  } $ } $}  $ } } $                          ARGOS THERAPEUTICS INC 10-K 04/02/2018,$Equity Compensation Plan Information  Plan Category  Number of securities  Weighted average & Number of securities remaining   to be issued upon  exercise price of % available for future issuance    exercise of  outstanding options, ! under equity compensation   outstanding options,  warrants and rights & plans (excluding securities in   warrants and rights      first column) (1)-%Equity compensation plans approved by~ *s ףp=[@  ~   security holders.&Equity compensation plans not approved ? ?    ? by security holders Total~ *s ףp=[@  ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4|pdX4rIn=PF0*8X> @             l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan InformDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } a/} $ } y} $ }  } $      ARGOS THERAPEUTICS INC 10-K 04/02/2018F>Security Ownership of Certain Beneficial Owners and Management,$Name and Address of Beneficial Owner Number of Percentage of   Shares Shares    Beneficially  Beneficially   Owned Owned 5% Stockholders:       , $Pharmstandard International S.A. (1)  ~ f   Gz2@ %ForArgos B.V. (2)~ ffffff@/'Directors and Named Executive Officers:,$Sander van Deventer, M.D., Ph.D. (3)~ n{Gz@ Hubert Birner, Ph.D. (4)~ \(\?Robert Carey (5)~ * *!Irackly Mtibelishvily (6)~ f * Igor Krol (7)~ ^ *Richard G. Morrison (8)~  *Jeffrey D. Abbey (9)~  *( Charles A. Nicolette, Ph.D. (10)~ f *Richard D. Katz (11)~  */'All executive officers and directors as~ ,(\!@ %!a group (10 persons) (12)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/Do lbVJ>P@-:N]cz=PF0*8X> @Z        l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain B PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } '} $ } $} $ } $} $                     ARGOS THERAPEUTICS INC 10-K 04/02/2018Director Independence~ ~  Audit Fees (1) ~ RL  ~   Audit-Related Fees (2)   ?    ?   Tax Fees (3)   ?    ?  All Other Fees (4)   ?    ? (  Total Fees for Services Provided ~ RL  ~  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*Zhsg'=C=PF0*8X> @J      l  H  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } } $ } : H     ARGOS THERAPEUTICS INC 10-K 04/02/2018PART IVExhibit NumberDescription of Exhibit    3.1 * - %Restated Certificate of Incorporation  % of the Registrant, as amended     @ 5 -Amended and Restated Bylaws of the Registrant1)(filed as Exhibit 3.2 to the Registrant?s7/Current Report on Form 8-K (File No. 001-35443)4,on February 18, 2014 and incorporated herein by reference)ffffff@-%Specimen Stock Certificate evidencing4,the shares of common stock (filed as Exhibit2*4.1 to Amendment No. 1 to the Registrant?s0(Registration Statement on Form S-1 (File/'No. 333-193137) on January 21, 2014 and)!incorporated herein by reference)@/'Fifth Amended and Restated Registration/'Rights Agreement, dated as of August 9,6.2013 (filed as Exhibit 4.2 to the Registrant?s0(Registration Statement on Form S-1 (File0(No. 333-193137) on December 30, 2013 and)!incorporated herein by reference)D~ lu- zV_k6|1 !"#$%&'()*+,-./0123456789:;<=>?   !333333@!5!-Amendment No. 1 to Fifth Amended and Restated"","$Registration Rights Agreement, dated##5#-September 29, 2014 (amending the Registrant?s$$/$'Fifth Amended and Restated Registration%%/%'Rights Agreement, dated August 9, 2013)&&1&)(filed as Exhibit 4.3 to the Registrant?s''4',Annual Report on Form 10-K on March 16, 2017((-(%and incorporated herein by reference))))*@*5*-Amendment No. 2 to Fifth Amended and Restated++,+$Registration Rights Agreement, dated,,0,(July 14, 2016 (amending the Registrant?s--/-'Fifth Amended and Restated Registration../.'Rights Agreement, dated August 9, 2013)//1/)(filed as Exhibit 4.2 to the Registrant?s00/0'Quarterly Report on Form 10-Q (File No.1161.001-35443) on August 15, 2016 and incorporated222herein by reference)3334@454-Amendment No. 3 to Fifth Amended and Restated55,5$Registration Rights Agreement, dated6606(March 6, 2017 (amending the Registrant?s77/7'Fifth Amended and Restated Registration88/8'Rights Agreement, dated August 9, 2013)9919)(filed as Exhibit 4.5 to the Registrant?s::4:,Annual Report on Form 10-K on March 16, 2017;;-;%and incorporated herein by reference)<<<=ffffff@=2=*Form of Warrant Agreement by and among the>>8>0Company and Computershare Inc. and Computershare??1?)Trust Company, N.A. (filed as Exhibit 4.1D{ l=V pLa~3.Og@ABCDEFG@@2@*to the Registrant?s Current Report on FormAA4A,8-K on July 29, 2016 and incorporated hereinBBB by reference)CD$E____________________________1F)Created by Morningstar Document Research.0G(http://documentresearch.morningstar.com/b1%=PF0*8X> @GGFFEE l  kO'2[>A  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } U} $ } = k     ARGOS THERAPEUTICS INC 10-K 04/02/2018PART IV@,$Registration Rights Agreement, dated  1 )June 15, 2017, by and between the Company  , $and Pharmstandard International S.A.  2 *(filed as Exhibit 10.2 to the Registrant?s  0 (Current Report on Form 8-K filed on June  6 .16, 2017 and incorporated herein by reference)333333@,$Registration Rights Agreement, dated6.September 22, 2017, by and between the Company3+and Invetech Pty Ltd (filed as Exhibit 10.22*to the Registrant?s Current Report on Form808-K filed on September 25, 2017 and incorporatedherein by reference)@,$Registration Rights Agreement, dated5-November 22, 2017, by and between the Company-%and Saint-Gobain Performance Plastics:2Corporation (filed as exhibit 10.2 to Registrant?s4,Current Report on Form 8-K filed on November6.28, 2017 and incorporated herein by reference) 10.1+4,2008 Stock Incentive Plan, as amended (filed80as Exhibit 10.2 to the Registrant?s Registration3+Statement on Form S-1 (File No. 333-193137)D lu'D4EGW< !"#$%&'()*+,-./0123456789:;<=>?  4 ,on December 30, 2013 and incorporated herein!!! by reference)""" #10.2+#0#(Form of Incentive Stock Option Agreement$$.$&under 2008 Stock Incentive Plan (filed%%8%0as Exhibit 10.3 to the Registrant?s Registration&&3&+Statement on Form S-1 (File No. 333-193137)''4',on December 30, 2013 and incorporated herein((( by reference)))) *10.3+*3*+Form of Nonstatutory Stock Option Agreement++.+&under 2008 Stock Incentive Plan (filed,,8,0as Exhibit 10.4 to the Registrant?s Registration--3-+Statement on Form S-1 (File No. 333-193137)..4.,on December 30, 2013 and incorporated herein/// by reference)000 110.4+141,2014 Stock Incentive Plan, as amended (filed2232+as Exhibit 10.1 to the Registrant?s Current3323*Report on Form 8-K filed on August 2, 201744-4%and incorporated herein by reference)555 610.5+606(Form of Incentive Stock Option Agreement77.7&under 2014 Stock Incentive Plan (filed8818)as Exhibit 10.6 to Amendment No. 1 to the99+9#Registrant?s Registration Statement::4:,on Form S-1 (File No. 333-193137) on January;;6;.21, 2014 and incorporated herein by reference)<<< =10.6+=3=+Form of Nonstatutory Stock Option Agreement>>.>&under 2014 Stock Incentive Plan (filed??1?)as Exhibit 10.7 to Amendment No. 1 to theD- l[ lx$7=W3Kb>@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_@@+@#Registrant?s Registration StatementAA4A,on Form S-1 (File No. 333-193137) on JanuaryBB6B.21, 2014 and incorporated herein by reference)CCCDffffff%@D0D(Lease Agreement, dated as of January 16,EE1E)2001, between the Registrant and HCP MOP,FF0F(as amended (filed as Exhibit 10.8 to theGG+G#Registrant?s Registration StatementHH5H-on Form S-1 (File No. 333-193137) on DecemberII6I.30, 2013 and incorporated herein by reference)JJJ K10.8+K3K+Employment Agreement between the RegistrantLL/L'and Jeffrey D. Abbey, dated December 9,MM7M/2013 (filed as Exhibit 10.9 to the Registrant?sNN0N(Registration Statement on Form S-1 (FileOO0O(No. 333-193137) on December 30, 2013 andPP)P!incorporated herein by reference)QQQ R10.9+R3R+Employment Agreement between the RegistrantSS0S(and Charles A. Nicolette, dated DecemberTT;T39, 2013 (filed as Exhibit 10.10 to the Registrant?sUU0U(Registration Statement on Form S-1 (FileVV0V(No. 333-193137) on December 30, 2013 andWW)W!incorporated herein by reference)XXY10.10+Y3Y+Employment Agreement between the RegistrantZZ0Z(and Lori R. Harrelson, dated December 9,[[8[02013 (filed as Exhibit 10.12 to the Registrant?s\\0\(Registration Statement on Form S-1 (File]]0](No. 333-193137) on December 30, 2013 and^^)^!incorporated herein by reference)__DO liTp[p+gx3z&`abcdefghij`10.11+`3`+Employment Agreement between the Registrantaa6a.and Richard D. Katz, dated July 1, 2016 (filedbb3b+as Exhibit 10.1 to the Registrant?s Currentcc/c'Report on Form 8-K (File No. 001-35443)dd0d(on July 11, 2016 and incorporated hereineee by reference)fg$h____________________________1i)Created by Morningstar Document Research.0j(http://documentresearch.morningstar.com/CY sB6*=PF0*8X> @jjiihh l  sU`lr  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } } $ } = s     ARGOS THERAPEUTICS INC 10-K 04/02/2018PART IV= ףp=$@1)Form of Indemnification Agreement between  6 .the Registrant and each director and executive  ; 3officer (filed as Exhibit 10.14 to the Registrant?s  0 (Registration Statement on Form S-1 (File  0 (No. 333-193137) on December 30, 2013 and  ) !incorporated herein by reference)10.13?-%Contract No. HHSN266200600019C, dated80September 30, 2006, by and among the Registrant,1)the National Institutes of Health and the5-National Institutes of Allergy and Infectious.&Diseases, as amended (filed as Exhibit.&10.15 to the Registrant?s Registration3+Statement on Form S-1 (File No. 333-193137)4,on December 30, 2013 and incorporated herein by reference)10.14?0(License Agreement, dated August 9, 2013,7/by and between the Registrant and Pharmstandard80S.A. (filed as Exhibit 10.16 to the Registrant?s0(Registration Statement on Form S-1 (File0(No. 333-193137) on December 30, 2013 and)!incorporated herein by reference)D lu"y-x)7T] j !"#$%&'()*+,-./0123456789:;<=>? 10.15? / 'License Agreement, dated July 31, 2013,!!/!'by and between the Registrant and Green""8"0Cross Corp. (filed as Exhibit 10.17 to Amendment##.#&No. 1 to the Registrant?s Registration$$3$+Statement on Form S-1 (File No. 333-193137)%%3%+on January 21, 2014 and incorporated herein&&& by reference)'''(10.16?(/('License Agreement, dated July 28, 2011,))1))by and between the Registrant and Celldex**2**Therapeutics, Inc. (filed as Exhibit 10.18++2+*to the Registrant?s Registration Statement,,5,-on Form S-1 (File No. 333-193137) on December--6-.30, 2013 and incorporated herein by reference).../10.17?/2/*License Agreement, dated January 10, 2000,00:02by and between the Registrant and Duke University,1111)as amended (filed as Exhibit 10.19 to the22+2#Registrant?s Registration Statement3353-on Form S-1 (File No. 333-193137) on December4464.30, 2013 and incorporated herein by reference)5556\(\$@616)Acknowledgement Agreement, dated November7727*4, 2013, by and between the Registrant and88/8'Pharmstandard International S.A. (filed9929*as Exhibit 10.20 to Amendment No. 1 to the::+:#Registrant?s Registration Statement;;4;,on Form S-1 (File No. 333-193137) on January<<6<.21, 2014 and incorporated herein by reference)===>10.19+>0>(2014 Employee Stock Purchase Plan (filed??2?*as Exhibit 10.21 to Amendment No. 1 to theD ldw(5H~(Cz,L@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_@@+@#Registrant?s Registration StatementAA4A,on Form S-1 (File No. 333-193137) on JanuaryBB6B.21, 2014 and incorporated herein by reference)CCCDffffff$@D/D'Lease Agreement, dated August 18, 2014,EE4E,by and between by and between the RegistrantFF1F)and TKC LXXII, LLC (filed as Exhibit 10.1GG2G*to the Registrant?s Current Report on FormHH/H'8-K on August 22, 2014 and incorporatedIIIherein by reference)JJJKQk$@K2K*Venture Loan and Security Agreement, datedLL9L1September 29, 2014, by and between the RegistrantMM2M*and Horizon Technology Finance CorporationNN4N,and Fortress Credit Co LLC (filed as ExhibitOO/O'10.1 to the Registrant?s Current ReportPP:P2on Form 8-K on September 30, 2014 and incorporatedQQQherein by reference)RRRSq= ףp$@S1S)Form of Warrant to Purchase Common Stock,TT8T0issued to Horizon Technology Finance CorporationUU/U'on September 29, 2014 (filed as ExhibitVV/V'10.2 to the Registrant?s Current ReportWW:W2on Form 8-K on September 30, 2014 and incorporatedXXXherein by reference)YYYZ(\u$@Z1Z)Form of Warrant to Purchase Common Stock,[[2[*issued to Drawbridge Special Opportunities\\7\/Fund LP on September 29, 2014 (filed as Exhibit]]/]'10.3 to the Registrant?s Current Report^^:^2on Form 8-K on September 30, 2014 and incorporated___herein by reference)Dp liRl4g~(y%9<`abcdefghijklmnopqr```a{Gz$@a,a$Development Agreement, dated Octoberbb/b'29, 2014, by and between the Registrantcc3c+and Invetech Lty Ltd (filed as Exhibit 10.5dd/d'to the Registrant?s Quarterly Report onee7e/Form 10-Q on November 14, 2014 and incorporatedfffherein by reference)gggh10.25?h,h$Development Agreement, dated Januaryii2i*5, 2015, by and between the Registrant andjj5j-Saint-Gobain Performance Plastics Corporationkk3k+(filed as Exhibit 10.27 to the Registrant?sll4l,Annual Report on Form 10-K on March 31, 2015mm-m%and incorporated herein by reference)no$p____________________________1q)Created by Morningstar Document Research.0r(http://documentresearch.morningstar.com/*hCV^ n% =PF0*8X> @rrqqpp l  7܅  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } } $ } :} $ 7     ARGOS THERAPEUTICS INC 10-K 04/02/2018PART IV5@-%Subsidiaries of the Registrant (filed  8 0as Exhibit 21.1 to the Registrant?s Registration  2 *Statement on Form S-1 on December 30, 2013  - %and incorporated herein by reference)    23.1 * . &Consent of PricewaterhouseCoopers LLP,3+an independent registered public accounting firm31.1 *,$Certification of principal executive.&officer pursuant to Rules 13a-14(a) or0(15d-14(a) of the Securities Exchange Act/'of 1934, as adopted pursuant to Section-%302 of the Sarbanes-Oxley Act of 200231.2 *,$Certification of principal financial.&officer pursuant to Rules 13a-14(a) or0(15d-14(a) of the Securities Exchange Act/'of 1934, as adopted pursuant to Section-%302 of the Sarbanes-Oxley Act of 200232.1 *4,Certifications pursuant to 18 U.S.C. Section0(1350, as adopted pursuant to Section 9061)of The Sarbanes-Oxley Act of 2002, by theD lux/ lD <6U  !"#$%&'()*+,-./0123456  0 (Registrant?s principal executive officer!!'!and principal financial officer"""#101.INS##XBRL Instance Document$$$%101.SCH%/%'XBRL Taxonomy Extension Schema Document&&&'101.CAL'4',XBRL Taxonomy Extension Calculation Linkbase(((Document)))*101.DEF*3*+XBRL Taxonomy Extension Definition Linkbase+++Document,,,-101.LAB-.-&XBRL Taxonomy Extension Label Linkbase...Document///0101.PRE0,0$XBRL Taxonomy Extension Presentation111Linkbase Document23$4____________________________15)Created by Morningstar Document Research.06(http://documentresearch.morningstar.com/2uqM ruI%5=PF0*8X> @6655441100..--++**((''%%##!!   l  *  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3)!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } '} 2} m *     ARGOS THERAPEUTICS INC 10-K 04/02/2018 SIGNATURES Signature Title Date    /s/ Jeffrey D. Abbey. &President, Chief Executive Officer and  April 2, 2018 Jeffrey D. Abbey Director % (Principal Executive Officer)   /s/ Richard D. Katz2*Vice President and Chief Financial Officer April 2, 2018Richard D. Katz, M.D.%(Principal Financial Officer)/s/ Lori R. Harrelson!Vice President of Finance April 2, 2018Lori R. Harrelson&(Principal Accounting Officer)/s/ Hubert BirnerDirector April 2, 2018Hubert Birner, Ph.D./s/ Robert F. CareyDirector April 2, 2018Robert F. Carey /s/ Igor KrolDirector April 2, 2018 Igor Krol/s/ Richard G. MorrisonDirector April 2, 2018Richard G. MorrisonD!l~r<}H$T0fqM !"#$%&'()   !!/s/ Irackly Mtibelishvily!Director! April 2, 2018"Irackly Mtibelishvily###$/s/ Sander van Deventer$Director$ April 2, 2018(% Sander van Deventer, M.D., Ph.D.&$'____________________________1()Created by Morningstar Document Research.0)(http://documentresearch.morningstar.com/iE=PF0*8X> @))(('' l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURESCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 2}       ARGOS THERAPEUTICS INC 10-K 04/02/20182*INDEX TO CONSOLIDATED FINANCIAL STATEMENTS  Page/ 'Report of Independent Registered Public F-2 Accounting Firm  * "Consolidated Financial Statements: #Consolidated Balance Sheets F-3-%Consolidated Statements of Operations F-40(Consolidated Statements of Comprehensive F-5 Loss-%Consolidated Statements of Changes in F-6&Stockholders? Equity (Deficit)-%Consolidated Statements of Cash Flows F-72*Notes to Consolidated Financial Statements F-8%Financial Statement Schedule:.&Schedule II ? Valuation and Qualifying F-43Accounts$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/@Dvj^R:o9f @ l  ?@  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIAL!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 7} $ } y} $ }  } $ ?                                 ARGOS THERAPEUTICS INC 10-K 04/02/2018#CONSOLIDATED BALANCE SHEETS December 31,  ~  ~  Assets     Current assets        ! Cash and cash equivalents ~ =   ~    Assets held for sale  ~ 2X   ~ $ Prepaid expenses~ *a9~ lLOther receivables~ 2O~ fTotal current assets~ ; ~ #Property and equipment, net~ f| ~ ΥRestricted cash~ *- ? Other assets~ 2~ 2 Total assets~ ,~ ,,$Liabilities and Stockholders? Equity (Deficit)Current liabilitiesAccounts payable~ 5H~ j>;Accrued expenses~ n/a~ #M( Current portion of notes payable~ bh~ /2*Current portion of other convertible notes ?~ n1)Current portion of manufacturing research~ N ?"and development obligation4,Current portion of capital lease obligations~  ?!Total current liabilities~ FL~ RGD lyma15@?06B-F6 ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > 1 )Convertible note payable to related party   ?   ~  .!&Long-term portion of other convertible!! !?!!!~ !c! "notes*#"Long-term portion of notes payable##~ #Js### #?#3$+Long-term portion of manufacturing research$$~ $5$$$ $?$"%and development obligation6&.Long-term portion of facility lease obligation&&~ & &&& &?&6'.Long-term portion of capital lease obligations''~ 'Zu''' '?'(Deferred liabilities((~ (^(((~ (r()Warrants))~ )9)))~ )R; )* Commitments** *?*** *?*&+Stockholders? equity (deficit)++++++++3,+Preferred stock $0.001 par value; 5,000,000,, ,?,,, ,?,1-)shares authorized as of December 31, 20161.)and 2017; 0 shares issued and outstanding(/ as of December 31, 2016 and 201720*Common stock $0.001 par value; 200,000,00000~ 0> 000~ 0N\011)shares authorized as of December 31, 201602(and 2017; 2,063,158 and 5,906,620 shares13)issued and outstanding as of December 31,4 2016 and 2017,5$Accumulated other comprehensive loss55~ 5555~ 5bQ5"6Additional paid-in capital66~ 6FP666~ 6r=V67Accumulated deficit77~ 7!ٰ777~ 7fz,7,8$Total stockholders? equity (deficit)88~ 8~x888~ 8e829*Total liabilities and stockholders? equity9~ 9,99~ 9,9: (deficit);$<____________________________1=)Created by Morningstar Document Research.0>(http://documentresearch.morningstar.com/BXh1q7;8j5 o:$=PF0*8X> @r>>==<<9999     l  $T  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } U5} $ } } $ } }  $ } } $ $                                 ARGOS THERAPEUTICS INC 10-K 04/02/2018-%CONSOLIDATED STATEMENTS OF OPERATIONS   Year Ended December 31,  ~ ~ ~  ~  Revenue ~   ~ 9  ~ s  Operating expenses             Research and development  ~    ~ "    ~ ) "General and administrative~ ~ b  ~   ,$Impairment of property and equipment ?~ ;-  ~  y Restructuring costs ? ?  ~  &p -%Gain on disposal of impaired property ? ?  ~  2W  Total operating expenses~ k~ 9   ~  X Operating loss~ > ~ {  ~   Other income (expense)    Interest income~ ~   ~   Interest expense~ Fu~   ~  ^' ,$Gain on early extinguishment of debt ? ?  ~  ӏ 1)Change in fair value of warrant liability ?~ {=  ~  f Other (loss) income~ F~ F  ~   #Other income (expense), net~ "8w~   ~  ^7 Net loss~ ^E+~ k[ ~  jXS 4,Net loss attributable to common stockholdersHzGRR@  fffff* $per share, basic and diluted,$Weighted average shares outstanding,~ :n>~ za  ~  + basic and dilutedDl{ocWSe6!]! ! " #  $!____________________________1")Created by Morningstar Document Research.0#(http://documentresearch.morningstar.com/ <=PF0*8X> @## "" !!        l  S  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } :} $ }  } $ }  }  $ } } $                      ARGOS THERAPEUTICS INC 10-K 04/02/20185-CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSYear Ended December 31,  ~ ~ ~  ~  Net loss ~ ^E+  ~ k[  ~ jXS ! Other comprehensive loss:            0 (Foreign currency translation (loss) gain  ~ nx   ~ :   ~ b 8 0Unrealized (loss) gain on short-term investments  ~ &   ~ >    ?  Total comprehensive loss~ s*~ ު[ ~  S $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|sg[O4NB6=PF0*8X> @j          l  2-?  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } $4} $ }  } $ } $}  $ } } $ }  } $ } } $ } } $ 2     ARGOS THERAPEUTICS INC 10-K 04/02/2018KCCONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (DEFICIT)Common Stock SharesCommon Stock Amount " Additional Paid-in Capital .&Accumulated Other Comprehensive IncomeAccumulated Deficit,$Total Stockholders? Equity (Deficit)               (Loss)' Balance as of December 31, 2014  ~ Z;  ~ ^  ~ b.8  ~ ^a  ~ pR  ~ y  Issuance of common stock  ~ 6   ~ ~   ~     ?    ?   ~ b (  Exercise of common stock options  ~ "   ~     ~ E     ?    ?   ~ F   Share-based compensation   ?    ?   ~ j     ?    ?   ~ j  /'Issuance of common stock under Employee~ ~    ~      ? ?~ ¥ "Stock Purchase Plan (ESPP)Issuance of warrants ? ?  ~  2   ? ?~ 2)!Cumulative translation adjustment ? ?    ?  ~ nx ?~ nx1)Unrealized gain on short-term investments ? ?    ?  ~ & ?~ &Net loss ? ?    ?   ?~ ^E+~ ^E+'Balance as of December 31, 2015~ n B~  ~  a;  ~ ~ 6}~ F-%Issuance of common stock and warrants~ E:~   ~     ? ?~ .&Issuance of restricted common stock to~ ~ B  ~  *3   ? ?~ j3 employees0(Issuance of fully vested common stock to~ (~   ~     ? ?~  directors Share-based compensation ? ?  ~  %-   ? ?~ %-+#Issuance of common stock under ESPP~ 3~   ~      ? ?~  #Common stock issuance costs ? ?  ~  ^   ? ?~ ^( Exercise of common stock options~ ~   ~  '   ? ?~  'Exercise of warrants~ +~   ~  fN   ? ?~ rN)!Cumulative translation adjustment ? ?    ?  ~ : ?~ :DAl]QE9F+;pg =(4 !"#$%&'()*+,-./011 )Unrealized gain on short-term investments   ?    ?    ?   ~ >    ?   ~ > !Net loss!! !?!!! !?!! !  ! ?! ! ! !?!!!~ !k[!!!~ !k[!'"Balance as of December 31, 2016""~ "}""~ "> "" ~ " FP" " ~ """~ "!ٰ""~ "~x"*#"Issuance of common stock under ATM##~ #>###~ #4## # ~ # F# # # #?### #?###~ #ޯ#/$'Issuance of warrants as payment of debt$$ $?$$$ $?$$ $ ~ $ P$ $ $ $?$$$ $?$$$~ $P$3%+Issuance of common stock as payment of debt%%~ %%%%~ %r%% % ~ % % % % %?%%% %?%%%~ %%.&&Issuance of restricted common stock to&&~ &&&&~ &&& & ~ & >u& & & &?&&& &?&&&~ &Du&' employees (Share-based compensation(( (?((( (?(( ( ~ ( R ( ( ( (?((( (?(((~ (R (+)#Issuance of common stock under ESPP))~ )R)))~ ))) ) ~ ) ) ) ) )?))) )?)))~ )))*!Cumulative translation adjustment** *?*** *?** *  * ?* * *~ *b*** *?***~ *b*+Net loss++ +?+++ +?++ +  + ?+ + + +?+++~ +jXS+++~ +jXS+',Balance as of December 31, 2017,,~ ,h,,~ ,N\,, ~ , r=V, , ~ ,bQ,,~ ,fz,,,~ ,e,-.$/____________________________10)Created by Morningstar Document Research.01(http://documentresearch.morningstar.com/(TgL8{"vj^6=PF0*8X> @1100//,,,, ,,,,,,"""" """"""        l  _u\ r  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } :} $ }  } $ }  }  $ }  } $ _                                 ARGOS THERAPEUTICS INC 10-K 04/02/2018-%CONSOLIDATED STATEMENTS OF CASH FLOWSYear Ended December 31,  ~ ~ ~  ~ , $Cash flows from operating activities             Net loss ~ ^E+  ~ k[  ~ jXS 0 (Adjustments to reconcile net loss to net            * "cash used in operating activities:%Depreciation and amortization~ )~ V :  ~  N; ( Share-based compensation expense~ j ~ ~7  ~  < 3+Common stock issued as payment for research~ "߀ ?    ?  and development services0(Common stock issued as payment for other ?~     ? services+#Amortization of debt issuance costs~ 5 ~ R    ? %Amortization of debt discount~ *~ B    ? *"Interest accrued on long-term debt~  ?  ~  ( 1)Impairment loss on property and equipment ?~ ;-  ~  y ,$Gain on early extinguishment of debt ? ?  ~   ,p 3+Decrease in fair value of warrant liability ?~ "  ~    -%Gain on disposal of impaired property ? ?  ~  2W  Other~ +~ f    ? 4,Changes in operating assets and liabilities:    .&Prepaid expenses and other receivables~ ] ~ F  ~  | Accounts payable~ ~ H  ~  Vx Accrued expenses~ 20~ :d+  ~  $ D@l{ocW| >R>z/k4l ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? . &Manufacturing research and development  ~    ~ |   ~  ! obligation"Deferred liabilities""~ ""Z"""~ """ " ~ " BI" -#%Net cash used in operating activities##~ #s###~ #nFM## # ~ # *֍# ,$$Cash flows from investing activities$$$$$$$$$ $ $ $ *%"Purchase of property and equipment%%~ %6ư%%%~ %UX%% % ~ % *% 4&,Proceeds from sale of property and equipment&& &?&&& &?&& & ~ & g& +'#Purchases of short-term investments''~ 'v\''' '?'' '  ' ?' 1()(Payment to) receipt from restricted cash((~ (#((( (?(( ( ~ ( *-( ))!account securing letter of credit8*0Proceeds from maturity of short-term investments**~ *Œ***~ *>=** *  * ?* 0+(Net cash provided by (used in) investing++~ + +++~ +++ + ~ + M+ , activities,-$Cash flows from financing activities--------- - - - 7./Proceeds from sale of common stock and warrants..~ .B ...~ .~.. . ~ . ޯ. /Stock issuance costs// /?///~ /"o// /  / ?/ /0'Proceeds from issuance of notes payable00~ 0000 0?00 0  0 ?0 -1%with detachable common stock warrants-2%Proceeds from issuance of convertible22 2?222 2?22 2 ~ 2 6n2 %3note payable to related party,4$Payment on facility lease obligation44~ 4^444~ 444 4  4 ?4 !5Payments on notes payable55~ 5555~ 555 5 ~ 5 6@5 -6%Payments on capital lease obligations66 6?666~ 6*66 6 ~ 6 Z)6 .7&Proceeds from exercise of common stock77 7?777~ 7rN77 7  7 ?7 8warrants09(Proceeds from exercise of employee stock99~ 9 999~ 9 99 9 ~ 9 9 :purchase plan rights.;&Proceeds from exercise of common stock;;~ ;E ;;;~ ;';; ;  ; ?; <options0=(Net cash provided by (used in) financing==~ =n===~ =E== = ~ = ,\= > activities0?(Effect of exchange rates changes on cash??~ ?}???~ ?":?? ? ~ ? ? DOl8"l!U*Y?y@ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ 0@(Net (decrease) increase in cash and cash@@~ @8@@@~ @) @@ @ ~ @ @ A equivalents!BCash and cash equivalentsBBBBBBBBB B B B CBeginning of periodCC~ CCCC~ C"+xCC C ~ C = C D End of periodD~ D"+xDD~ D= DD ~ D  D 8E0Supplemental disclosure of cash flow informationEEEEEEEEE E E E FCash paid for interestF~ FdFF~ F:FF ~ F .F 4G,Supplemental disclosure of noncash investingGGGGGGGGG G G G  Hand financing activities1I)Issuance of common stock for research andI~ I"߀II~ III  I $?I &Jdevelopment and other services2K*Issuance of warrants in exchange for earlyK K$?KK K$?KK ~ K PK Lextinguishment of debt1M)Issuance of convertible notes in exchangeM M$?MM M$?MM ~ M bM (N for early extinguishment of debt0O(Issuance of common stock in exchange forO O$?OO O$?OO ~ O O $Pearly extinguishment of debt8Q0Interest capitalized on construction-in-progressQ~ Q:5QQ~ Q/QQ  Q $?Q 4R,Purchases of property and equipment includedR~ R:JRR~ RRR ~ R ÖR 0S(in accounts payable and accrued expenses/T'Recognition of asset and facility leaseT~ TmTT~ T֫TT  T $?T -U%obligation related to construction ofV new property1W)Stock issuance costs included in accountsW W$?WW~ WAWW  W $?W $Xpayable and accrued expenses/Y'Property recognized under capital leaseY Y$?YY~ YBԐYY  Y $?Y Z obligations[$\____________________________1])Created by Morningstar Document Research.0^(http://documentresearch.morningstar.com/BlX6j*^7 eCpJq@(Yi=PF0*8X> @Z+^^ ]] \\ YYYYYY WWWWWW TTTTTT RRRRRR QQQQQQ OOOOOO MMMMMM KKKKKK IIIIII FFFFFF DDDDDD      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } %} $ }  } $ } $}  $ } $} $ }  } $      ARGOS THERAPEUTICS INC 10-K 04/02/2018.&2. Fair Value of Financial Instruments Quoted Prices Significant   Significant  Balance as of    in Active  Other   Unobservable   December 31,    Markets for   Observable  Inputs ~    Identical Assets  Inputs   (Level 3)    (Level 1)   (Level 2) Assets                Money-market funds~  X  $?   $?  ~  X #Restricted cash ? long-term~ *- ?    ?  ~ *-"Total assets at fair value~   $?   $?  ~   Liabilities     Warrants $? $? ~  9  ~ 9'Total liabilities at fair value $? $? ~  9  ~ 9$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/68 znbV(, Vi(eYM%=PF0*8X> @"$                l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } %} $      ARGOS THERAPEUTICS INC 10-K 04/02/2018.&2. Fair Value of Financial Instruments Quoted Prices Significant   Significant  Balance as of    in Active  Other   Unobservable   December 31,    Markets for   Observable  Inputs ~    Identical Assets  Inputs   (Level 3)    (Level 1)   (Level 2) Assets                Money-market funds~  $?   $?  ~ "Total assets at fair value~  $?   $?  ~  Liabilities     Warrants $? $? ~  R;   ~ R; 'Total liabilities at fair value $? $? ~  R;   ~ R; $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/47 znbV(, VRF:=PF0*8X> @"$                l  Ȼ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } m)} $ } } $      ARGOS THERAPEUTICS INC 10-K 04/02/2018.&2. Fair Value of Financial Instruments'Balance as of December 31, 2015 $?* "Issuance of warrants at fair value  ~ : ' Unrealized gain during the year  ~ " ' Balance as of December 31, 2016 ~ 9 ' Unrealized gain during the year  ~   ' Balance as of December 31, 2017 ~ R;  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hznbVHI=1 =PF0*8X> @2   l  2  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } !} $ }  } $ } $}  $ } $} $ }  } $      ARGOS THERAPEUTICS INC 10-K 04/02/2018.&2. Fair Value of Financial InstrumentsAs of December 31, 2016   Amortized Cost  Gross  Gross   Aggregate   Basis   Unrealized   Unrealized  Fair       Holding  Holding  Value       Gains  Losses Money-market funds ~  X    $?   $?  ~  X  #Restricted cash ? long-term~ *- ?    ?  ~ *-~   $?   $?  ~  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.znbVnATp=PF0*8X> @              l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } a} $      ARGOS THERAPEUTICS INC 10-K 04/02/2018.&2. Fair Value of Financial InstrumentsAs of December 31, 2017   Amortized Cost  Gross  Gross   Aggregate   Basis   Unrealized   Unrealized  Fair       Holding  Holding  Value       Gains  Losses Money-market funds ~    $?   $?  ~  ~  $?   $?  ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|znbVnA]=PF0*8X> @              l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } U5} $ } y} $ } y}  $ } y} $                        ARGOS THERAPEUTICS INC 10-K 04/02/2018G?Impairment of Centerpoint Facility and Construction-in-Progress Severance andLease and Other   Total   Other Employee  Facility Costs   Costs' Balance as of December 31, 2016  $?   $?   $?  Restructuring costs  ~     ~ b   ~ &p 4 ,Acceleration of stock options and restricted  ~ fi>    ?   ~ fi>  stock Cash payments~  ~ jd  ~  pQ 'Balance as of December 31, 2017 $? $?   $? $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0aUI=pG(h=PF0*8X> @z         l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 8} $ } } $ } y}  $ }  } $                             ARGOS THERAPEUTICS INC 10-K 04/02/2018!4. Property and Equipment Useful Life~  ~     (Years)& Office furniture and equipment  ~   ~ N'(  ~  '  Computer equipment  ~    ~ $>   ~ F_<  Computer software  ~    ~    ~   Laboratory equipment  ~    ~ ~v\   ~ BMq Leasehold improvements~ ~ *  ~  * 3+Assets related to facility lease obligation~ F    ?  Construction-in-progress~ VL    ?     )!Total property and equipment, net~ X   ~  q) 7/Less: Accumulated depreciation and amortization~ b$  ~  4     #Property and equipment, net~ f|  ~  Υ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:Y {oc-yX;zl`T,=PF0*8X> @Z       l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } I"} $      ARGOS THERAPEUTICS INC 10-K 04/02/201891Centerpoint Facility and Construction-in-Progress$Year ended December 31, 2015~ )$ Year ended December 31, 2016  ~ V : $ Year ended December 31, 2017  ~ N;   $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,ocWK=1%=PF0*8X> @2    l  '  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 1} $ } y} $ } y} $                              ARGOS THERAPEUTICS INC 10-K 04/02/20185. Income Taxes December 31,  ~  ~ 1 )U.S. federal and state net operating loss ~ PS  ~ *U   carryforwards0 (Foreign net operating loss carryforwards  ~ &]   ~ d " Contribution carryforwards  ~ VB   ~ j" ( Research and development credits~ 6U~ jInvestment tax credits~ n~ f Share-based compensation~ r`~ UOther accruals~ 7~ &Deferred revenue~ hD~ ?Property and equipment~ ~ !Total deferred tax assets~ u~ ~/'Valuation allowance for deferred assets~ "$~ 2Net deferred tax assets $? $?$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<I ym=|cA+%xP=PF0*8X> @R      l  F  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 7} $ } } $ }  } U} $ } } $ }  } U} $ } I} $ }  } U      ARGOS THERAPEUTICS INC 10-K 04/02/20185. Income Taxes~ ~ ~  ~    Amount " Percent of Pretax Earnings  Amount " Percent of Pretax Earnings  Amount " Percent of Pretax Earnings' U.S. federal tax statutory rate ~    ~  % ~ *   ~  % ~    ~  %, $State taxes (net of federal benefit)  ~ ʉ    @ %  ~    ~   %  ~     ~   %- %U.S. federal research and development  ~ }    333333@ %  ~ V~    @ %  ~ B    @ %  tax credits$Other nondeductible expenses~ ?ffffff %)  ~  ~g.   %)~ Zsx %)-%Increase in unrecognized tax benefits~ :' %)  ~  N    %)~ : %)*"Change in effective state tax rate~ ީH %)  ~  e   %)~ ~  %)6.Expiration of NOL & contribution carryforwards~ VUI) %)    ?  ~  %)~ R333333ӿ %)2*Adjustment for change in federal effective ?~  %)    ?  ~  %)~  lY %)tax rate1)Change in fair value of warrant liability ?~  %)    ?  ~  %)~ 28ffffff2@ %%Change in valuation allowance~ L6 %)  ~  7  33333@ %)~  G@ %#Deferred tax asset true-ups~  %)  ~    ? %~ ffffff@ %"Provision for income taxes $?~  %   $?  ~  % $?~  %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>0ym~&Kek_S+=PF0*8X> @          l  4W  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } $4} $ }  } $ }  }  $ }  } $                      ARGOS THERAPEUTICS INC 10-K 04/02/20185. Income Taxes~ ~~  ~   Beginning balance ~ ⇃  ~ b  ~ r 0 (Gross increase for tax positions related  ~ '   ~    ~   to current periods3 +Gross (decrease) increase for tax positions   ?    ?    ?  related to prior periodsEnding balance~ b~ r ~  2 $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|ym" =PF0*8X> @b        l  )l)p  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2) 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } $4} $ } } $ } y} $ )                                 ARGOS THERAPEUTICS INC 10-K 04/02/20186.6. Notes Payable and Convertible Notes Payable December 31, December 31,  ~  ~ 0 (Notes payable under the venture loan and  ~ V   $? - %security agreement, including accrued interest2 *Less debt discount and debt issuance costs  ~ q    ? 0(Notes payable under the venture loan and~ l ?security agreement, net2*Convertible note payable to Pharmstandard, ?~ "including accrued interest-%Convertible note payable to Invetech, ?~ ^d"including accrued interest1)Convertible note payable to Saint-Gobain, ?~ F"including accrued interest2*Note payable to Medinet, including accrued~ ц~ .interestOther notes payable~ ~  Total debt~ "0~ 0(Less current portion of convertible note ?~ .&payable to Invetech, including accruedinterest0(Less current portion of convertible note ?~ 2*payable to Saint-Gobain, including accruedinterestD lrfZN.PC_.@ ! " # $ % & ' ( / 'Less current portion of note payable to   ?   ~ bV +!#Medinet, including accrued interest3"+Less current portion of other notes payable""~ "C"""~ "'".#&Long-term portion of notes payable and#~ #Js###~ ##!$convertible notes payable%$&____________________________1')Created by Morningstar Document Research.0((http://documentresearch.morningstar.com/`j;=PF0*8X> @J ((''&&##    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } m)} $ } I } $ }  }  $ }      ARGOS THERAPEUTICS INC 10-K 04/02/2018 10. Warrants*"Type of Warrant and ClassificationNumber of Shares Exercise Price   Expiration   Date of Issuance          Date(s) Common stock - Equity  9/29/14   ~ @   ffffff@   9/29/21 Common stock - Equity  3/4/16   ~ N0  ~    3/4/21 Common stock - Equity  6/29/16   ~ *   ~    6/29/21 Common stock - Liability  8/2/16   ~   ~    8/02/21Common stock - Equity3/6/17~ "N~  j   3/06/22$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,||p@5)=PF0*8X> @Z      l  }  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } <(} $ } } $      ARGOS THERAPEUTICS INC 10-K 04/02/2018 10. Warrants August 2016   Warrants Exercise price ~   Expiration date   August 2, 2021 ) !Total shares issuable on exercise  ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T|pA|=PF0*8X> @2   l  ?  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } :} $ } y} $} $ } U} $                             ARGOS THERAPEUTICS INC 10-K 04/02/2018 10. WarrantsDecember 31, 2016December 31, 2017     " Exercise price of warrants ~   ~  . &Closing underlying stock price on date ~   ~    of valuation' Expected stock price volatility  ~ R %  ~  % Expected life (in years)RQ@p= ף @Risk-free interest ratezG? %RQ@ %Expected dividend yield~  %~  %-%Valuation per common share underlyingq= ףN@\(\? each warrant80Total liability for warrants on the consolidated~ 9~ R;  balance sheet1)Decrease in fair value in the years ended~ {=~ f"December 31, 2016 and 2017$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/: |pd=nUn=PF0*8X> @r     l  b  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 0.} $ } y} $ } y}  $ } y} $                     ARGOS THERAPEUTICS INC 10-K 04/02/2018G?2014 Stock Incentive Plan and 2014 Employee Stock Purchase PlanYear Ended December 31,  ~ ~ ~  ~  Research and development ~ Fq  ~   ~ r " General and administrative  ~ &t   ~  8   ~ r  Restructuring costs   ?    ?   ~ G . &Total share-based compensation expense ~ j   ~ @I  ~ < $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*&haUI=V=PF0*8X> @j           l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } -} $ }  } $} $ }  } $} $ } } $                    ARGOS THERAPEUTICS INC 10-K 04/02/2018F>Valuation Assumptions for Stock Option Plans and the 2014 ESPP~ ~~  ~   Risk-free interest rate   ffffff@ %   ? %   Gz@ % Expected dividend yield  ~  %  ~  %  ~  %- %Expected stock option term (in years)  ~    ~    ~   Expected volatility  ~ ^ %  ~ J %  ~ Z % $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(0TbVJ>`=PF0*8X> @2    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } +} $ } <} $} $ }  } $} $ } } $                    ARGOS THERAPEUTICS INC 10-K 04/02/2018F>Valuation Assumptions for Stock Option Plans and the 2014 ESPP~ ~~  ~   Risk-free interest rate    0.07% - 0.26 %    0.47 - 0.50 %    0.69 - 0.79 % Expected dividend yield  ~  %  ~  %  ~  %, $Expected ESPP rights term (in years)   ?    ?    ?  Expected volatility   45% - 58 %    113% - 141 %    141% - 210 % $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(aTbVJ> P~p=PF0*8X> @2    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 7} $ }  } $ }  } $                           ARGOS THERAPEUTICS INC 10-K 04/02/20180(Other Information for Stock Option Plans Number ofWeightedWeighted   Aggregate   Shares  Average Exercise  Average   Intrinsic      Price   Contractual  Value         Term          (in years)+ #Outstanding as of December 31, 2016 ~ V   Y^@     Granted~ 2OQW@    Exercised ? $?    Cancelled~ -QeX@   +#Outstanding as of December 31, 2017~ *s ףp=[@RQ@   $?+#Exercisable as of December 31, 2017~ ^ q= ף@]@(\@   $?6.Vested and expected to vest as of December 31,~  \( \@p= ף@   $?~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6Q xl`T47ZN@4 =PF0*8X> @            l  E  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } }  }  } $ }  } $ } } $ } U} $      ARGOS THERAPEUTICS INC 10-K 04/02/20180(Other Information for Stock Option Plans1)Exercise Price or Range of Exercise PriceOptions OutstandingWeighted Average  Options Exercisable         Contractual Life         (Years)  333333 @   ~ r    {Gz#@   ~  ~ n to~   ~ U    (\@   ~  ~  to 333333g@  ~ r     333333@   ~ & ףp= 'k@ tok@~   {Gz@   ~   (\@ to@~  Q @   ~  ~ *s RQ@   ~  z $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0U xl`T%*b =PF0*8X> @J       l  w  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } I"} $ }  } $      ARGOS THERAPEUTICS INC 10-K 04/02/201813. Commitments~ ~ $~   ~ ' ~   ~ B( ~   ~ ' ~   ~ 6   Thereafter  ~  $Total minimum lease payments~ `$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|ym9y9c=PF0*8X> @* l  J  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } U5} $ } y} $ } y}  $ } y} $                      ARGOS THERAPEUTICS INC 10-K 04/02/201815. Net Loss Per ShareYear Ended December 31,  ~ ~ ~  ~        4 ,Net loss attributable to common stockholders ~ ^E+  ~ k[  ~ jXS 3 +Weighted average common shares outstanding,  ~ :n>   ~ za   ~ +  basic and diluted1)Net loss per share attributable to commonHzGRR@  fffff* 'stockholders, basic and diluted$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,"|~rf+}6 =PF0*8X> @j          l  '  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } y#} $ }  } $ }  }  $ }  } $                    ARGOS THERAPEUTICS INC 10-K 04/02/201815. Net Loss Per ShareYear Ended December 31,  ~ ~ ~  ~ ! Stock options outstanding  ~ .    ~     ~ L  Warrants outstanding  ~ @   ~ ο   ~  * % Convertible notes outstanding   ?    ?   ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(nT~rf+`c=PF0*8X> @:      l  ?  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 0} $ } y} $ } y}  $ } y} $ } } $      ARGOS THERAPEUTICS INC 10-K 04/02/2018/'16. Selected Quarterly Data (unaudited) Quarter Ended    March 31,  June 30,   September 30,   December 31,  ~  ~  ~  ~  Revenue ~   ~   ~   ~    Operating expenses:                 Research and development  ~ bC   ~ bV/   ~ :   ~  t "General and administrative~ ”~   ~  Z  ~ &0(Impairment of property and equipment (1) ? ?    ?  ~ ;-Operating loss~ f~   ~  #  ~ UA#Other income (expense), net~ ~ ^  ~  ._  ~ {     Net loss~ ~ n ~    ~ V-%Net loss per share, basic and dilutedGz&ףp= W#  ףp=   ,$Weighted average shares outstanding,~ nD~ 2O  ~  >s  ~ }basic and diluted$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:3ymaU$o tzR=PF0*8X> @            l  \Z  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 1} $ } y} $ } y}  $ } y} $ } y} $      ARGOS THERAPEUTICS INC 10-K 04/02/2018/'16. Selected Quarterly Data (unaudited) Quarter Ended    March 31,  June 30,   September 30,   December 31,  ~  ~  ~  ~  Revenue ~ l  ~ @  ~ C  ~ e  Operating expenses:                 Research and development  ~    ~ 8   ~ F   ~ x "General and administrative~ .~   ~    ~ jq0(Impairment of property and equipment (1)~ k| ?    ?  ~  Restructuring costs (2)~ 1~ j  ~  q)   ?1)Gain on disposal of impaired property (3) ? ?    ?  ~ 2WOperating loss~ jl~   ~  ^  ~ fp'Other income (expense), net (4)~ Vؾ~ v  ~  ey  ~      Net loss~ DB~ 6 ~  Í  ~ w-%Net loss per share, basic and dilutedRQ'Q  p= ף  RQؿ,$Weighted average shares outstanding,~ 2~~ D~  ~  ⸱  ~ 0basic and diluted$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>D0ymaU$o7i=PF0*8X> @            l  {k  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)License Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } I"} $      ARGOS THERAPEUTICS INC 10-K 04/02/2018.&Deferred Tax Asset Valuation Allowance Additions    Balance at   Charged to   Charged to   Increases   Balance at    Beginning  Expenses  Other      End of Year   of Year  (a)  Accounts$ Year Ended December 31, 2017 ~  C ~    $?  $? ~ $ Year Ended December 31, 2016 ~ . ~ n   $?  $? ~  C$Year Ended December 31, 2015~ )~    $?   $?~ .$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,.|znbVD-w =PF0*8X> @                 l  Sz  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation Al PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 7} 2      ARGOS THERAPEUTICS INC 10-K 04/02/2018License Agreement1)Development Milestones (for each Product)Payment6 .Upfront payment (on signing license agreement)2 *Shares of ARGS common stock equal to $3.24  million [**] [**] [**] [**] [**] [**] [**] [**] [**] [**]( Total Development Milestone Fees$11.74 million$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0wk#tT4n=PF0*8X> @ l  x  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense AgreementLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } 1      ARGOS THERAPEUTICS INC 10-K 04/02/2018 PATENT RIGHTSLicensed Know-How   1 )Sequences of antibody that binds to PD-1: [**] [**] [**] [**]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4{oRF:.a=PF0*8X> @ l  ڔ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } } 0      ARGOS THERAPEUTICS INC 10-K 04/02/2018#Lummy (Hong Kong) Co., Ltd.Milestone EventMilestone Payment [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/08yma) iI)=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co Ltd!CERTIFICATIONS PURSUANT TO 18 U!CERTIFICATIONS PURSUANT TO (1)U } } 0      ARGOS THERAPEUTICS INC 10-K 04/02/2018#Lummy (Hong Kong) Co., Ltd.Milestone EventMilestone Payment [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**]$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2lyma) iI) =PF0*8X> @ l  X  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO (1)U } $ } } U      ARGOS THERAPEUTICS INC 10-K 04/02/20181)CERTIFICATIONS PURSUANT TO 18 U.S.C. 1350 By:/S/ JEFFREY D. ABBEY   Jeffrey D. Abbey   Chief Executive Officer    April 2, 2018  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@wk_Sxl`8=PF0*8X> @ l  ;  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??@ARGOS THERAPEUTICS INCPART IOur Development Programs!Phase 2 Combination Therapy Cli!Description and Development Sta PART II PART II (1)!Consolidated Statements of Oper!Consolidated Balance Sheet Data!Results of Operations YearOverY!Research and Development Expens Cash Flows!Liability for Warrants and the ShareBased Compensation!Contractual Obligations and Com PART IIISummary Compensation Table!Outstanding Equity Awards as of!2017 Compensation of NonEmploye!Equity Compensation Plan Inform!Security Ownership of Certain BDirector Independence PART IV PART IV (1) PART IV (2) PART IV (3) SIGNATURES!INDEX TO CONSOLIDATED FINANCIALCONSOLIDATED BALANCE SHEETS!CONSOLIDATED STATEMENTS OF (1)!CONSOLIDATED STATEMENTS OF COMP!CONSOLIDATED STATEMENTS OF CHAN!CONSOLIDATED STATEMENTS OF CASH!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!Impairment of Centerpoint Facil4 Property and Equipment!Centerpoint Facility and Constr5 Income Taxes5 Income Taxes (1)5 Income Taxes (2)!6 Notes Payable and Convertible 10 Warrants10 Warrants (1)10 Warrants (2)!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock!Valuation Assumptions for S (1)!Other Information for Stock Opt!Other Information for Stock (1)13 Commitments15 Net Loss Per Share15 Net Loss Per Share (1)!16 Selected Quarterly Data unau!16 Selected Quarterly Data (1)!Deferred Tax Asset Valuation AlLicense Agreement PATENT RIGHTSLummy Hong Kong Co LtdLummy Hong Kong Co Ltd (1)!CERTIFICATIONS PURSUANT TO 18 UU } $ } } 2      ARGOS THERAPEUTICS INC 10-K 04/02/20181)CERTIFICATIONS PURSUANT TO 18 U.S.C. 1350 By:!/S/ RICHARD D. KATZ, M.D.   Richard D. Katz, M.D.  2 *Vice President and Chief Financial Officer    April 2, 2018  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@wk_S[OC=PF0*8X> @ Root Entry FBook    !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~